Activity Preview

Live

Ketamine/Esketamine in the Treatment of Serious and Persistent Depression: Practical Considerations

Activity Type:

  • On Demand


Release Date: 4/15/2020

Expiration Date: 4/15/2021

  • AMA PRA Category 1: 1
  • Nursing Continuing Professional Development: 1
  • Participation: 1

Register

Overview

This presentation briefly reviews the science and pharmacology that led to the development of ketamine and esketamine as a treatment for neuropsychiatric disorders. It specifically focuses on major issues to be contemplated when considering recommending treatment with ketamine or esketamine to treat severe and persistent major depressive disorder. And, critically reviews the existing data from a wide range of clinical trials and attempt to incorporate this data into clinical decision making processes.

Pricing

FREE - $0

Funding for this initiative was made possible (in part) by Grant No. 1H79SM080818-01 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government. 

Learning Objectives

  • Explain indications for use of ketamine in the treatment of serious and persistent mood disorders
  • Evaluate clinical trials examining the efficacy and safety of ketamine and esketamine
  • Describe challenges to implementing ketamine into practice

Target Audience

Nurse/Nurse Practitioner, Physician (non-psychiatrist), Physician Assistant, Psychiatrist, Pharmacist

Instructional Level

Intermediate

Estimated Time to Complete

Estimated Duration: 1.0 hour
Program Start Date: April 16, 2020
Program End Date: April 16, 2021

How to Earn Credit

Participants who wish to earn AMA PRA Category 1 Credit™, nursing continuing professional development pharmacology contact hours (NCPD, formerly CNE), or a certificate of participation may do so by completing all sections of the course, including the evaluation. A multiple choice quiz is provided based on the content. A passing score of 75% must be achieved. Retakes are available for the test. After evaluating the program, course participants will be provided with an opportunity to claim hours of participation and print an official CME certificate (physicians), NCPD certificate (nursing), or certificate of participation (other professions) showing the completion date and hours earned.

Continuing Education Credit

Physicians

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The APA designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses/Nurse Practitioners

The American Psychiatric Nurses Association is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Faculty and Planner Disclosures

Instructor

  • Gerard Sanacora, MD, PhD, Associate Professor and Director of the Yale Depression Research Program, Yale University. Disclosures - Off-label medication use will be discussed; Stock: Biohaven Pharmaceuticals; Consultant: Allergan, Alkermes, AstraZeneca, Avanier, Axsome Therapeutics, Pharmaceuticals, Biohaven Pharmaceuticals, BristolMyers Squibb, Clexio Biosciences, EMA Wellness, Epiodyne, Intra-Cellular Therapies, Janssen, Merck & Co., Naurex, Navitor, NeruoRx, Novartis, Noven Pharmaceuticals, Otsuka, Perception Neuroscience, Praxis Therapeutics, Sage Pharmaceuticals, Servier Pharmaceuticals, Taisho Pharmaceuticals, Teva, Valeant, and Vistagen Therapeutics; Grant/Research: AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Hoffman La-Roche, Merck, Naurex, and Servier over the last 36 months. Free medication was provided to GS for an NIH-sponsored study by Sanofi-Aventis.Other: Co-inventor on a patent ‘Glutamate agents in the treatment of mental disorders’ (Patent number: 8778979), and a U.S. Provisional Patent Application No. 047162-7177P1 (00754) filed on August 20, 2018 by Yale University Office of Cooperative Research OCR 7451 US01.

Planners

  • Teri Brister, PhD, LPC, National Alliance on Mental Illness. Reports no financial relationships with commercial interests.
  • Tristan Gorrindo, MD, American Psychiatric Association. Reports no financial relationships with commercial interests.
  • Donna Rolin, PhD, APRN, University of Texas at Austin. Reports no financial relationships with commercial interests. 

Accessibility for Participants with Disabilities

The American Psychiatric Association is committed to ensuring accessibility of its website to people with disabilities. If you have trouble accessing any of APA’s online resources, please contact us at 202-559-3900 for assistance.

Hardware/Software Requierments

This internet-based CME activity is best experienced using Internet Explorer 8+, Mozilla Firefox 3+, Safari 4+. This website requires that JavaScript and session cookies be enabled. Certain activities may require additional software to view multimedia, presentation, or printable versions of the content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Adobe Acrobat, Microsoft PowerPoint, and Windows Media Player.

Optimal System Configuration

  • Browser: Firefox (latest version), Internet Explorer 8.0+, Safari 7.0+, Microsoft Edge (latest version) or Google Chrome (latest version)
  • Operating System: Windows XP+ or Mac OS X 10.4+
  • Flash Player: Adobe Flash Player 10.3+ 
  • Internet Connection: 1 Mbps or higher

Minimum Requirements

  • Windows PC: 500-MHz Pentium II; Windows XP or higher; 128 MB RAM; Video Card at least 64MB of video memory; Macromedia Flash Player 10.3 or higher; Sound Card at least 16-bit; audio playback with speakers for programs with video content
  • Macintosh:Mac OS X 10.4+ or higher with latest updates installed; 1.83MHz Intel Core Duo or faster; RAM: 128MB or more; Video Card: at least 64MB of video memory; Sound Card: at least 16-bit; audio playback with speakers for programs with video content

For assistance: Contact educme@psych.org for questions about this course | Contact SMIadviserHelp@psych.org for technical assistance

Register